ES2186717T3 - Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc. - Google Patents

Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc.

Info

Publication number
ES2186717T3
ES2186717T3 ES95915611T ES95915611T ES2186717T3 ES 2186717 T3 ES2186717 T3 ES 2186717T3 ES 95915611 T ES95915611 T ES 95915611T ES 95915611 T ES95915611 T ES 95915611T ES 2186717 T3 ES2186717 T3 ES 2186717T3
Authority
ES
Spain
Prior art keywords
peptides
class
ctl
activity
cyto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95915611T
Other languages
English (en)
Inventor
Carol Clayberger
Alan M Krensky
Peter Parham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Application granted granted Critical
Publication of ES2186717T3 publication Critical patent/ES2186717T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE USAN FRAGMENTOS DE LOS DOMINIOS POLIMORFICOS DE LOS DOMINIOS DEL ANTIGENO DE CLASE I HLA PARA MODULAR LA ACTIVIDAD DE CELULAT. LOS PEPTIDOS SON DESDE EL {AL}1 O {AL}2- DOMINANTES, PARTICULARMENTE DE LOS ANTIGENOS HLA-A, COMPUESTOS B. LOS PEPTIDOS PUEDEN SER CONJUGADOS CON OTROS COMPUESTOS PARA SER USADOS EN DIAGNOSTICO Y TERAPIA.LOS PEPTIDOS PUEDEN BLOQUEAR LA LISIS, LA PROLIFERACION DE CTL O TIENEN OTROS EFECTOS REGULADORES.
ES95915611T 1994-04-05 1995-04-05 Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc. Expired - Lifetime ES2186717T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/222,851 US5723128A (en) 1987-01-30 1994-04-05 Cytotoxic T-cell lymphocyte ("CTL") activity regulation by class I MHC peptides

Publications (1)

Publication Number Publication Date
ES2186717T3 true ES2186717T3 (es) 2003-05-16

Family

ID=22833972

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95915611T Expired - Lifetime ES2186717T3 (es) 1994-04-05 1995-04-05 Regulacion de la actividad de los linfocitos t citotoxicos ("ctl") mediante peptidos de la clase i del mhc.

Country Status (8)

Country Link
US (1) US5723128A (es)
EP (1) EP0753005B1 (es)
JP (1) JPH10501791A (es)
AT (1) ATE231884T1 (es)
CA (1) CA2187193A1 (es)
DE (1) DE69529515T2 (es)
ES (1) ES2186717T3 (es)
WO (1) WO1995026979A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011834B1 (en) * 1987-01-30 2006-03-14 The Board Of Trustees Of Leland Stanford Junior University Immunomodulating dimers
US6696061B1 (en) * 1992-08-11 2004-02-24 President And Fellows Of Harvard College Immunomodulatory peptides
CA2142007C (en) * 1992-08-11 2007-10-30 Robert Glen Urban Immunomodulatory peptides
US6162434A (en) * 1995-05-03 2000-12-19 Sangstat Medical Corporation Cytomodulating peptide for inhibiting lymphocyte activity
US6436903B1 (en) * 1996-05-22 2002-08-20 Stanford University (Board Of Trustees Of The Leland Standford Junior University) Immunomodulating compounds comprising d-isomers of amino acids
US6696545B1 (en) 1997-04-11 2004-02-24 Sangstat Medical Corporation Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation
BR9808529B1 (pt) * 1997-04-11 2010-10-05 oligopeptìdeo.
US7109170B2 (en) * 1999-06-16 2006-09-19 Saint Louis University Region of factor IXa protease domain that interacts with factor VIIIa and methods therefor
US7094413B2 (en) * 2002-01-24 2006-08-22 Sangstat Medical Corporation Combined therapy for treatment of HIV infection
AU2003286611A1 (en) * 2002-10-24 2004-05-13 Sangstat Medical Corporation Cytomodulating peptides and methods for treating neurological disorders
WO2005053727A2 (en) * 2003-11-29 2005-06-16 Sangstat Medical Corporation Pharmaceutical compositions for bioactive peptide agents
WO2006031226A1 (en) * 2004-09-13 2006-03-23 Saint Louis University Region of factor ixa protease domain that interacts with factor viiia and methods therefor
US20090023895A1 (en) 2006-02-07 2009-01-22 Nec Corporation Hla-binding peptide, precursor thereof, and dna fragment and recombinant vector coding for said hla-binding peptide
EP2434014B1 (en) 2006-10-12 2014-12-10 Nec Corporation HLA-binding peptide, precursor thereof, DNA fragment and recombinant vector encoding the same
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL69686A (en) * 1983-09-11 1988-03-31 Yeda Res & Dev Compositions containing cell membrane proteins and process for their preparation
US4681760A (en) * 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
WO1988005784A1 (en) * 1987-01-30 1988-08-11 The Board Of Trustees Of The Leland Stanford Junio Lymphocyte inhibition by hla peptides
US5888512A (en) * 1987-01-30 1999-03-30 Board Of Trustees Of The Leland Stanford Junior University Lymphocyte activity regulation by HLA peptides
JPH03504493A (ja) * 1988-02-12 1991-10-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 細胞性免疫の発生及び操作のための合成ペプチドの使用
EP0459978B1 (en) * 1989-03-03 1997-07-16 The Regents Of The University Of California Class i mhc modulation of surface receptor activity
US5073540A (en) * 1989-05-15 1991-12-17 Receptron Composite binding site drugs
CA2081582A1 (en) * 1991-11-05 1993-05-06 Teodorica Bugawan Methods and reagents for hla class i dna typing

Also Published As

Publication number Publication date
EP0753005A1 (en) 1997-01-15
JPH10501791A (ja) 1998-02-17
WO1995026979A1 (en) 1995-10-12
DE69529515T2 (de) 2003-06-12
DE69529515D1 (de) 2003-03-06
CA2187193A1 (en) 1995-10-12
EP0753005A4 (en) 1997-06-18
ATE231884T1 (de) 2003-02-15
US5723128A (en) 1998-03-03
EP0753005B1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
ES2150949T3 (es) Regulacion de la actividad de linfocitos con la ayuda de peptidos hla.
ATE231884T1 (de) Die regulation der aktivität zytotoxischer t- zelllymphozyten mit peptiden der mhc-klasse i
NO943967D0 (no) Suppresjon av proliferative responser og induksjon av toleranse med polymorf klasse II MHC allopeptider
DK549188A (da) Lymfocythaemmende hla-peptider
Storkus et al. Peptide-induced modulation of target cell sensitivity to natural killing
DK0935607T3 (da) Oplöselige monovalente og multivalente MHC klasse II-fusionsproteiner samt anvendelser deraf
DK0643726T3 (da) Peptider af humant p53-protein til anvendelse i sammensætninger, som inducerer humant T-celle-respons, og humane p53-protei
ES2111027T3 (es) Aparato para aplicar sujetadores quirurgicos.
DK240090A (da) Dna og anvendelse deraf
DE69329344D1 (de) Spezifische modulationen des immunsystems
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
DK0912176T3 (da) Anvendelse af pyridylalkan-, pyridylalken- og/eller pyridylalkynsyreamider til behandling af tumorer eller immunosuppression
NO985975L (no) Blandinger og fremgangsmÕter for frembringelse av farmakologisk aktive preparater og anvendelser derav
DK0584266T3 (da) Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
EP0959896A4 (en) COMPOSITIONS BASED ON THE HUMAN THYROTROPIN RECEPTOR AND THEIR USE
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
DE69431531D1 (de) Immortalisierte menschliche fötale osteoblastenzellen
ATE139259T1 (de) Selbstantigen der primären lebercirrhose
DE69132682D1 (de) Zellwachstumsinhibitoren
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos
ATE248914T1 (de) Allogenes vakzin und synthesemethode für selbiges
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
EP0659217A4 (en) CLONING AND EXPRESSION OF THE RECEPTOR -g (b) APP-C100.
UA42900A1 (uk) Пристрій для підводної витяжки хребта